Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NHS-IL2 + SBRT in Advanced Melanoma
NCT01973608Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2014
- Primary completion
- Apr 2015
- Modality
- Antibody Conjugates, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of EMD 521873 in melanoma, sponsored by EMD Serono. Started Jan 2014; status: terminated.
02
Drugs
EMD 521873
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01973608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01973608.